



SelectImmune Pharma releases new film about immunotherapy

Today we are proud to present a new film entitled "*Immunotherapy - a complement to antibiotics*". The film tells the story about SelectImmune Pharma's drug development program and the scientific discoveries that have defined new and exciting tools for treating infections.

SelectImmune is developing several drug candidates with exciting potential. In the film you will meet the multinational and talented research team and hear their stories about their favourite molecules and technologies. You will also meet Dr. Björn Wullt, who has used innate immunotherapy to treat patients with bladder pain syndrome.

Understanding why infections make us ill is crucial to better target the cause of disease. The film discusses this question and how molecular discoveries are being used to develop effective new therapies.

We hope that you will find the film informative and inspiring.

The film is produced by journalists Calle Magnell and Fredrik Kron, in collaboration with Jan-Olof Bengtsson. An English version will be released soon.

To watch the film, please follow this link, https://www.youtube.com/watch?v=J9Gw_D9IF6I or visit our website, selectimmune.com.

For more information, please contact:

Catharina Svanborg

Chairman of the board SelectImmune Pharma AB

Phone: +46 709 42 65 49

E-mail: catharina.svanborg@med.lu.se

SelectImmune Pharma is a pharmaceutical company whose shares are traded on the Spotlight Stock Market. The company goal is to develop new immunotherapies, which act as immune enhancers and offer alternatives to antibiotics.

Bacterial infections affect large parts of the population and are becoming increasingly difficult to treat due to increasing antibiotic resistance. SelectImmune Pharma develops immunotherapies that can supplement or replace antibiotics. Urinary tract infections (UTI) are one of the world's most common infectious diseases, affecting about 150 million people each year. The need for alternative treatments for bacterial infections is currently very large as are potential markets.